Photo taken from Jun Gong/X
Jun 5, 2024, 09:58
Jun Gong: Dr. Cigliola PhII SURE trial of neoadj sacituzumab govitecan for cis-ineligible MIBC
Jun Gong, Medical Oncologist and Researcher in Gastrointestinal and Genitourinary cancers at Cedars-Sinai, shared a post on X:
“Dr. Cigliola PhII SURE trial of neoadj sacituzumab govitecan for cis-ineligible MIBC
18/21 patients finished all 4C 47.6% pCR rate but 3 deaths (1 treatment-related) after 1C, required amendment to lower dose and require GCSF, several patients with cCR.”
Source: Jun Gong/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19